Key facts
- This page summarizes Sandy Macrae's Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Mar 2022, 16:16.
Sandy Macrae - 25 Feb 2022 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)
- Reporting relationship
- President, CEO and Director, Director
- Issuer ticker
- SGMO
- Reported as of
- 25 Feb 2022
- Net transaction value
- -$294,351
- SEC form
- 4
- Accepted by SEC
- 01 Mar 2022, 16:16:01 UTC
- Next SEC filing
- 06 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- Alexander D. Macrae, by /s/ Ron A. Metzger, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sandy Macrae filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 01 Mar 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$294,351.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SGMO
transaction
Common Stock
Tax liability
- Transaction value
- $294,351
- Shares
- -49,890
- Change %
- -14%
- Price
- $5.90
- Shares after
- 297,176
- Date
- 25 Feb 2022
- Ownership
- Direct
- Footnotes
- F1, F2
SGMO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +224,000
- Change %
- +75%
- Price
- $0.000000
- Shares after
- 521,176
- Date
- 25 Feb 2022
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SGMO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +604,800
- Change %
- Price
- $0.000000
- Shares after
- 604,800
- Date
- 25 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 604,800
- Exercise price
- $5.90
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents shares underlying the portions of restricted stock unit ("RSU") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").
Footnote F2
Includes: (a) 10,633 shares resulting from the February 25, 2022 final vesting installment of the Reporting Person's February 25, 2019 RSU grant, (b) 32,756 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 56,261 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023 and (c) 30,173 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 92,254 shares subject to such RSU grant that will vest in two remaining annual installments of 46,120 shares and 46,134 shares on February 25, 2023 and 2024, respectively. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Footnote F3
Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Footnote F4
One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.